Sponsored By
Regulatory
FDA facing rising pressure to exercise CBD ‘enforcement discretion’
Regulatory
FDA facing rising pressure to exercise CBD ‘enforcement discretion’FDA facing rising pressure to exercise CBD ‘enforcement discretion’
Lawmakers seek a policy of enforcement discretion but that wouldn’t address the underlying problem facing the hemp industry—namely FDA’s position that CBD cannot be marketed in a dietary supplement.
Subscribe and receive the latest updates on trends, data, events and more.
Join 57,000+ members of the natural products community.